Decision Resources, finds that surveyed neurologists have low awareness of Novartis-Mitsubishi Tanabes, Gilenia (Fingolimod), among the surveyed oral emerging therapies for the treatment of multiple sclerosis (MS).

Decision Resources study forecasts that boosted by atrial fibrillation drugs, by 2019 the market will reach $7 billion.

Merck & Co. has cut down 15 percent of their staff force following a strategy after last year merger with rival Schering-Plough Corp. They have decided to shut down eight manufacturing plants and 8 R&D worldwide facilities.

Decision Resources forecasts that the non-small-cell lung cancer drug market in Brazil will reach $240 million by 2014

India-based generic drug maker, Lupin Ltd. said they will start market study to acquire companies in the Latin Americas region. They target Mexican and Brazilian markets.

Pfizer said they voluntarily decided to withdraw from the market, injectable drug Mylotarg (Gemtuzumab Ozogamicin for Injection, indicated to treat acute myeloid leukemia. A clinical study showed a higher death rate and no benefit for patients. It´s the first drug to be approved by abbreviated process from the FDA to be withdrawn from the market.

A report by the U.S. Centers for Disease Control and Prevention (CDC) that enrolled more than 16 thousand high school students, revealed that almost 20 percent of them, take or has taken prescription medication that was not prescribed for them. Data on tobacco, food and sex comsuption.

A study published on the May edition of the American Journal of Preventive Medicines revealed that about 34 percent of teenage girls between 13 to 17 years old have been vaccinated with Merck & Co. Gardasil (Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18), Vaccine Recombinant) vaccine against human papillomavirus (HPV),

Novo Nordisk A/S anticipated that their Type 2 diabetes drug, Victoza (Liraglutide) will be launched in Japan by June.

According to Teva Pharmaceutical Industries Ltd., Chief Financial Officer, Eyal Desheh, the world´s top generic company will not meet sales forecast of $16 billion in 2010.

Johnson & Johnson Inc. announced acquirement of (through its business unit Centocor Ortho Biotech) British privately-held company RespiVert Ltd. the company is dedicated to developing treatments for asthma and other lung diseases.

Pfizer Inc. announced that they will cut 6 thousand jobs in the next five years, at the same time will close eight manufacturing plants in Ireland, Puerto Rico and the United States, and will reduce activities at six factories in those countries, plus Germany and Britain.

Astellas Pharma Inc. announced acquisition of OSI Pharmaceuticals Inc. in $4 billion, after a 11 percent increase in their offer. This ends a two month hostile negotiation.

Pfizer Inc. announced acquisition of Ergonex Pharma GmbH experimental pulmonary arterial hypertension drug rights, Terguride.

Follow is an estimated study by Evaluatepharma for 2016 sales, growth and future market share of the 10 biggest worldwide pharmaceutical companies. 2009 Comparative Chart.

Follow is an estimated study by Evaluatepharma for 2016 sales, growth and future market share of the 10 biggest worldwide pharmaceutical companies. 2009 Comparative Chart.

A new study published in the May issue of Pediatrics, indicate that many pharmacies in the United States poorly translate their prescriptions instructions to their Spanish-speaking customers, consequently creating a life-threatening situation for them.

Purdue Pharma L.P announced that the Food and Drug Administration approved a new formula for blockbuster painkiller, OxyContin (Oxycodone HCI) a potent opioid. The idea is to avoid the drug from being cut, broken, chewed, crushed or dissolved to release more medication.

In a very interesting Bloomberg TV interview, Pfizer Inc. Pharmaceutical President, Martin Mackay, said that their products will reach blockbuster status in the next few years. According to the executive, Pfizer is going through “the golden age of drug discovery”. Mackay said they have specialties for Alzheimer, Cancer and painkiller drugs.

According to market speculations, the world largest drug maker, Pfizer Inc, will make an offer for the U.S. generics company, Mylan Inc. The company is the main manufacturer of economic version drugs of the United States.